PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35021069-0	2022	Development of Asciminib, a Novel Allosteric Inhibitor of BCR-ABL1.	asciminib	15-24	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	62-66	
35021069-4	2022	Asciminib is a promising investigational agent in development that allosterically targets BCR-ABL1 in a non-ATP-competitive manner.	asciminib	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	94-98